The Patient's Perspective on Proton Radiotherapy of Skull Base Meningioma: A Retrospective Cross-Sectional Survey.
cross sectional study
patient report
proton therapy
radiotherapy
skull base meningioma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
03
2021
accepted:
13
06
2022
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
23
8
2022
Statut:
epublish
Résumé
Radiotherapy plays an important role in the management of skull base meningioma. The aim of the study was to investigate patient-reported outcomes. A questionnaire of 20 items was sent to 192 patients with meningioma of the skull base who have been treated with proton therapy at a single institution. The survey included dichotomous, scaling, and open questions about symptoms, social distancing, rehabilitation, work, reintegration, limitations in recreational activities, as well as daily life activities and correlating diagnoses. Additionally, symptoms were reported retrospectively by the patients at different time points. In total, 128 patients (66.7%) responded. The median age at the time of RT was 55 years (range: 28-91); the majority were female (79%). The median time between the treatment of meningioma and the survey was 38.5 months (range: 7-100). The most common initial symptoms were visual impairment ( Besides neurological deficits, patients with skull base meningioma experience a variety of unspecific symptoms, which can be most limiting in daily life. Even successful treatment does not necessarily translate into the alleviation of those symptoms. A greater focus on the characterization of those symptom complexes is necessary. Greater focus on functional structures such as the hippocampus might improve the results. Due to the retrospective character, this study is hypothesis-generating.
Sections du résumé
Background
UNASSIGNED
Radiotherapy plays an important role in the management of skull base meningioma. The aim of the study was to investigate patient-reported outcomes.
Methods
UNASSIGNED
A questionnaire of 20 items was sent to 192 patients with meningioma of the skull base who have been treated with proton therapy at a single institution. The survey included dichotomous, scaling, and open questions about symptoms, social distancing, rehabilitation, work, reintegration, limitations in recreational activities, as well as daily life activities and correlating diagnoses. Additionally, symptoms were reported retrospectively by the patients at different time points. In total, 128 patients (66.7%) responded. The median age at the time of RT was 55 years (range: 28-91); the majority were female (79%). The median time between the treatment of meningioma and the survey was 38.5 months (range: 7-100).
Results
UNASSIGNED
The most common initial symptoms were visual impairment (
Conclusion
UNASSIGNED
Besides neurological deficits, patients with skull base meningioma experience a variety of unspecific symptoms, which can be most limiting in daily life. Even successful treatment does not necessarily translate into the alleviation of those symptoms. A greater focus on the characterization of those symptom complexes is necessary. Greater focus on functional structures such as the hippocampus might improve the results. Due to the retrospective character, this study is hypothesis-generating.
Identifiants
pubmed: 35992835
doi: 10.3389/fonc.2022.677181
pmc: PMC9390067
doi:
Types de publication
Journal Article
Langues
eng
Pagination
677181Informations de copyright
Copyright © 2022 Seidensaal, Sailer, Harrabi, von Gehlen, Seidensaal, Weykamp, Bernhardt, Debus and Herfarth.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Oncol. 2016 Sep;17(9):e383-91
pubmed: 27599143
Skull Base. 2004 Feb;14(1):53-60; discussion 61
pubmed: 16145585
Neuro Oncol. 2019 Jan 14;21(Suppl 1):i32-i43
pubmed: 30649488
Radiat Oncol. 2018 Mar 27;13(1):54
pubmed: 29587795
Clin Transl Radiat Oncol. 2020 Sep 12;25:52-60
pubmed: 33024844
Radiother Oncol. 2019 Jul;136:44-49
pubmed: 31015128
World Neurosurg. 2017 Oct;106:145-151
pubmed: 28666914
Neurooncol Pract. 2020 Jun;7(3):320-328
pubmed: 32528713
JAMA Oncol. 2015 Oct;1(7):918-30
pubmed: 26247417
Biol Psychiatry. 2005 Jan 1;57(1):21-6
pubmed: 15607296
J Neurooncol. 2000 Jul;48(3):233-41
pubmed: 11100821
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e495-500
pubmed: 22285662
Biol Psychiatry. 2009 May 1;65(9):812-8
pubmed: 19028381
Qual Life Res. 1996 Feb;5(1):139-50
pubmed: 8901377
J Clin Oncol. 2014 Dec 1;32(34):3810-6
pubmed: 25349290
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Lancet Oncol. 2011 Feb;12(2):127-36
pubmed: 21236730
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):733-9
pubmed: 23703492
Oper Neurosurg (Hagerstown). 2018 Dec 1;15(suppl_1):S245-S294
pubmed: 30260447
J Clin Oncol. 2020 Apr 1;38(10):1019-1029
pubmed: 32058845
J Neurosurg Sci. 2011 Dec;55(4):319-28
pubmed: 22198584
Radiat Oncol. 2012 Dec 29;7:226
pubmed: 23273161
J Clin Oncol. 2006 Oct 20;24(30):4882-7
pubmed: 17050873
Cancer. 2018 Jan 1;124(1):161-166
pubmed: 28902404
Support Care Cancer. 2012 Jul;20(7):1441-7
pubmed: 21773676
Cereb Cortex. 2015 Mar;25(3):680-702
pubmed: 24068551
Neuropsychiatr Dis Treat. 2018 Feb 09;14:479-494
pubmed: 29445285
Neurooncol Pract. 2020 Jan;7(1):77-85
pubmed: 32257286
Br J Cancer. 2007 Sep 3;97(5):612-8
pubmed: 17653075
Support Care Cancer. 2014 Sep;22(9):2593-8
pubmed: 25015058